Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Systemic Risk Assessment for Complex, Interdependent Systems: A Research Agenda.

Risk analysis : an official publication of the Society for Risk Analysis·2026
Same author

Protocolized reduction of non-resuscitation fluids versus usual care in septic shock patients (REDUSE): a randomized multicentre feasibility trial.

Critical care (London, England)·2024
Same author

Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Dual-Energy X-Ray Absorptiometry Derived Adiposity Measures and Pre-Frailty/Frailty among Norwegian Adults: The Tromsø Study 2007-2015.

The journal of nutrition, health & aging·2023
Same author

Burden of in-hospital care in oesophageal cancer: national population-based study.

BJS open·2021
Same author

Impact of surgical resection rate on survival in gastric cancer: nationwide study.

BJS open·2021

Related Experiment Video

Updated: Jun 23, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Alpha-helix targeting reduces amyloid-beta peptide toxicity.

C Nerelius1, A Sandegren, H Sargsyan

  • 1Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, The Biomedical Centre, Uppsala, Sweden.

Proceedings of the National Academy of Sciences of the United States of America
|May 22, 2009
PubMed
Summary

Researchers developed novel compounds that stabilize a specific region of amyloid-beta (Abeta) peptides. This approach reduces Abeta toxicity and neurodegeneration, offering a new strategy for Alzheimer's disease treatment.

More Related Videos

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
10:01

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

Related Experiment Videos

Last Updated: Jun 23, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
10:01

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Amyloid-beta (Abeta) peptide oligomers are implicated in Alzheimer's disease neuropathology.
  • Existing Abeta polymerization inhibitors have limitations, including nonspecific aggregation and potential for increased toxicity.

Purpose of the Study:

  • To develop a novel therapeutic strategy targeting the Abeta peptide.
  • To design specific inhibitors that stabilize a key Abeta conformation, counteracting toxic oligomer formation.

Main Methods:

  • Designed ligands to bind and stabilize the 13-26 region of Abeta in an alpha-helical conformation.
  • Tested compound efficacy in cell cultures, hippocampal slice preparations, and Drosophila melanogaster models.
  • Assessed Abeta toxicity, aggregation properties, lifespan, locomotor activity, and neurodegeneration.

Main Results:

  • Two distinct compound classes successfully stabilized the Abeta alpha-helix.
  • Compounds reduced Abeta toxicity in vitro and in ex vivo preparations without nonspecific aggregation.
  • In vivo studies showed prolonged lifespan, improved locomotor activity, and reduced neurodegeneration in Drosophila.

Conclusions:

  • Stabilizing the central Abeta alpha-helix is a viable strategy to inhibit toxic polymerization.
  • This approach offers a promising therapeutic avenue for Alzheimer's disease, distinct from current inhibitor methods.